Compare Amphastar Pharmaceuticals Inc (AMPH) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs DENTSPLY SIRONA Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while DENTSPLY SIRONA Inc trades at $11.69 (market cap $2.32B). The key difference: DENTSPLY SIRONA Inc is far larger — about 2.7× Amphastar Pharmaceuticals Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | XRAY | |
|---|---|---|
Market Cap | $863.95M | $2.32B |
Sector | Health | Health |
52-Week High | $30.81 | $14.68 |
52-Week Low | $16.87 | $9.64 |
Enterprise Value | $1.26B | $4.40B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
DENTSPLY SIRONA (XRAY) trades at $12.12, down 7.97% in 24 hours, with a bearish technical signal and support near $12. The company reported Q2 2026 EPS of $0.52, beating expectations, but revenue declined 4.1% year-over-year. Financials show negative net income margins and ROE, though gross margins remain solid at 49.52%. Recent news highlights institutional stake increases and strategic partnerships, such as the expanded Medline Sinclair relationship in Canada.
The outlook is cautious due to persistent revenue declines and profitability challenges, offset by cost-cutting efforts and digital dentistry growth. Risks include weak European demand and high debt levels, while analyst consensus is Hold with a $11.50 price target, indicating limited near-term upside amid turnaround execution uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
